Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E13.65 EPS (ttm)1.24 Insider Own1.57% Shs Outstand12.84M Perf Week1.98%
Market Cap212.00M Forward P/E8.38 EPS next Y2.02 Insider Trans0.00% Shs Float12.31M Perf Month4.31%
Income15.88M PEG0.68 EPS next Q0.42 Inst Own93.03% Short Float / Ratio0.46% / 10.20 Perf Quarter6.03%
Sales37.94M P/S5.59 EPS this Y32.14% Inst Trans0.23% Short Interest0.06M Perf Half Y-2.70%
Book/sh22.19 P/B0.76 EPS next Y9.46% ROA5.22% Target Price24.00 Perf Year-12.80%
Cash/sh2.48 P/C6.83 EPS next 5Y20.00% ROE5.72% 52W Range15.26 - 19.99 Perf YTD-3.85%
Dividend- P/FCF20.11 EPS past 5Y35.42% ROI5.72% 52W High-15.16% Beta0.30
Dividend %- Quick Ratio- Sales past 5Y11.93% Gross Margin81.06% 52W Low11.14% ATR0.34
Employees21 Current Ratio- Sales Q/Q-34.73% Oper. Margin41.71% RSI (14)62.82 Volatility2.42% 1.94%
OptionableNo Debt/Eq0.08 EPS Q/Q-30.92% Profit Margin41.84% Rel Volume0.62 Prev Close16.32
ShortableYes LT Debt/Eq0.00 EarningsNov 09 BMO Payout0.00% Avg Volume5.61K Price16.96
Recom1.00 SMA204.39% SMA505.90% SMA2001.12% Volume3,487 Change3.92%
Nov-09-23 07:30AM
Nov-06-23 04:05PM
Oct-30-23 08:00AM
Oct-18-23 08:00AM
Oct-11-23 08:00AM
04:05PM Loading…
Oct-03-23 04:05PM
Sep-28-23 06:34PM
Sep-26-23 04:07PM
Aug-17-23 09:00AM
Aug-09-23 04:05PM
Aug-08-23 08:00AM
Jul-27-23 05:43PM
Jul-17-23 04:05PM
Jun-28-23 04:05PM
May-11-23 09:00AM
07:00AM Loading…
May-02-23 04:36PM
Apr-03-23 07:30AM
Mar-31-23 08:00AM
SWK Holdings Corp. engages in financial and asset management in the field of pharmaceuticals. The company offers capital and investments in life science companies, institutions, and inventors. It operates through the Finance Receivables and Pharmaceutical Development segments. The Finance Receivables segment is a healthcare capital provider which offers customized financing solutions to a broad range of life science companies, institutions, and investors. It is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Pharmaceutical Development segment strategy is to utilize the Peptelligence platform to create a wholly-owned portfolio of milestone and royalty income by out-licensing the technology. The company was founded in July 1996 and is headquartered in Dallas, TX.